Skip to main content
9955 search results for:

Chronic Lymphocytic Leukemia 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 07-05-2024 | Chronic Lymphocytic Leukemia | Online First

    Inflammation mediated angiogenesis in chronic lymphocytic leukemia

    Chronic inflammation has been identified in leukemias as an essential regulator of angiogenesis. B-chronic lymphocytic leukemia (CLL) cells secrete high levels of vascular endothelial growth factor (VEGF) and hypoxia inducible factor 1 alpha …

  2. 15-04-2024 | Chronic Lymphocytic Leukemia | Online First

    Bi-clonal Chronic Lymphocytic Leukemia

  3. 18-04-2024 | Chronic Lymphocytic Leukemia | Online First

    American Society of Hematology (ASH) update 2023—chronic lymphocytic leukemia

    In recent years, there has been massive advances in the treatment of chronic lymphocytic leukemia (CLL) from chemoimmunotherapy to the combination of targeted agents (BTK inhibitors, BCL2 inhibitors, anti-CD20 antibody), which should be …

  4. Open Access 01-12-2024 | Chronic Lymphocytic Leukemia | OriginalPaper

    Progressive multifocal leukoencephalopathy in a patient with B-cell chronic lymphocytic leukemia after COVID-19 vaccination, complicated with COVID-19 and mucormycosis: a case report

    Progressive multifocal leukoencephalopathy (PML) is a rare and fatal opportunistic viral demyelinating infectious disease of the central nervous system (CNS), initially described in 1958 in patients with lymphoproliferative and myeloproliferative …

  5. Open Access 18-04-2024 | Chronic Lymphocytic Leukemia | Online First

    COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study

    Patients with chronic lymphocytic leukemia (CLL) are at high risk of developing severe COVID-19. The present study was undertaken to elucidate COVID-19 related morbidity and mortality in CLL patients treated with venetoclax. We present a …

  6. 21-03-2024 | Chronic Lymphocytic Leukemia | Letter

    Effective treatment of pleural effusion in chronic lymphocytic leukemia with acalabrutinib: a case report

  7. Open Access 03-02-2024 | Chronic Lymphocytic Leukemia | OriginalPaper

    Conditional survival to assess prognosis in patients with chronic lymphocytic leukemia

    Biomarkers in chronic lymphocytic leukemia (CLL) allow assessment of prognosis. However, the validity of current prognostic biomarkers based on a single assessment point remains unclear for patients who have survived one or more years. Conditional …

  8. Open Access 01-12-2024 | Chronic Lymphocytic Leukemia | ReviewPaper

    Advances in epigenetic alterations of chronic lymphocytic leukemia: from pathogenesis to treatment

    Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with alterations in genetic expression and epigenetic modifications. In recent years, the new insight into epigenetics in the pathogenesis of CLL has been developed considerably …

  9. Open Access 18-01-2024 | Chronic Lymphocytic Leukemia | OriginalPaper

    Prediction of severe infections in chronic lymphocytic leukemia: a simple risk score to stratify patients at diagnosis

    Chronic Lymphocytic Leukemia (CLL) is well-known for increasing susceptibility to infections. Factors such as immune dysregulation, IGHV status, hypogammaglobulinemia, and patient comorbidity and treatment, contribute to higher infection rates and …

  10. 16-03-2024 | Chronic Lymphocytic Leukemia | Online First

    Characteristics of chronic lymphocytic leukemia in Japan: Comprehensive analysis of the CLLRSG-01 study

    Chronic lymphocytic leukemia (CLL) is rare in Japan. We conducted the nationwide, prospective observational study CLLRSG-01 to clarify the current state of CLL in Japan and to make accurate international comparisons by preparing naturally …

  11. 13-03-2024 | Chronic Lymphocytic Leukemia | Online First

    Optimization of mHealth behavioral interventions for patients with chronic lymphocytic leukemia: the HEALTH4CLL study

    Chronic lymphocytic leukemia (CLL) is characterized by malignant involvement of the bone marrow, peripheral blood, and lymphoid organs with clonal B cells. It is the most prevalent form of leukemia in the Western world, is typically diagnosed in …

  12. 01-02-2024 | Ibrutinib | ReviewPaper

    How Do We Manage Chronic Lymphocytic Leukemia in India

    In this review article, we have focused on the experience of three clinical hematologists practicing in different environments in different regions of India on the management issues in CLL. Cancer Institute (WIA) is a charitable nonprofit public …

  13. Open Access 04-01-2024 | Chronic Lymphocytic Leukemia | ReviewPaper

    Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease

    Time-limited treatment of chronic lymphocytic leukemia (CLL) has been the standard-of-care for decades: The first chemotherapy-based regimens, such

  14. 06-01-2024 | Zanubrutinib | OriginalPaper

    Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

    Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia in adults, accounting for approximately 30% of all leukemias in the USA [ 1 ]. Although advances in treatment have dramatically improved the outcome of patients with CLL, a …

  15. 27-12-2023 | Chronic Lymphocytic Leukemia | OriginalPaper

    Investigation of fatty acid metabolism in chronic lymphocytic leukemia to guide clinical outcome and therapy

    Chronic lymphocytic leukemia (CLL) is the most common leukemia in the West. With CLL’s heterogeneity, some people still develop disease refractory and relapse despite advances in treatment. Thus, early diagnosis and treatment of high-risk CLL …

  16. Open Access 06-03-2024 | Ibrutinib | Online First

    Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study

    We conducted an observational study (FIRE) to understand the effectiveness and safety outcomes of ibrutinib in patients with chronic lymphocytic leukemia (CLL) in France, after a maximum follow-up of five years. Patients were included according to …

  17. 05-12-2023 | Chronic Lymphocytic Leukemia | OriginalPaper

    Caring for an Individual with Chronic Lymphocytic Leukemia (CLL): Understanding Family Caregivers’ Perceptions of Social Support, Caregiver Burden, and Unmet Support Needs

    Family caregivers (FCs) of a patient with chronic lymphocytic leukemia (CLL) can encounter unpredictable challenges and care demands. They can experience high levels of burden, a loss of self-care, and poor quality of life. Their receipt of social …

  18. Open Access 01-02-2024 | Chronic Lymphocytic Leukemia | OriginalPaper

    Unexpected chronic lymphocytic leukemia B cell activation by bisphosphonates

    Chronic lymphocytic leukemia (CLL) is a disease of the elderly, often presenting comorbidities like osteoporosis and requiring, in a relevant proportion of cases, treatment with bisphosphonates (BPs). This class of drugs was shown in preclinical …

  19. 23-11-2023 | Chronic Lymphocytic Leukemia | OriginalPaper

    NOTCH pathway mutation contributes to inferior prognosis in HBV-infected chronic lymphocytic leukemia

    Chronic lymphocytic leukemia (CLL) patients with hepatitis B virus (HBV) infection have a poor prognosis, underlying mechanism remains unclear. NOTCH mutations are frequent in CLL and associated with disease progression and drug resistance. It is …

  20. Open Access 29-02-2024 | Tumor Lysis Syndrome | Online First

    Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study

    Venetoclax is active in both frontline and relapsed/refractory settings for the treatment of chronic lymphocytic leukemia (CLL). Although the prevalence and severity of tumor lysis syndrome (TLS) are well characterized in clinical trials …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.